Performance of laboratories in antimicrobial susceptibility testing of MB-16-01
Antibiotics | MIC | Antibiotics | Disk | ||||||
---|---|---|---|---|---|---|---|---|---|
S | I | R | IND | S | I | R | IND | ||
CLSI group A | |||||||||
Azithromycin | 21 | Clarithromycin | 1 | ||||||
Erythromycin | 1 | 212 | Erythromycin | 1 | 24 | ||||
Clindamycin | 215 | Clindamycin | 1 | 24 | |||||
Oxacillin | 206 | Oxacillin | 2 | 18 | |||||
Cefoxitin | 2 | Cefoxitin | 8 | ||||||
Oxacillin (Cefoxitin) | 11 | Oxacillin (Cefoxitin) | 4 | 1 | |||||
Penicillin G | 2 | 196 | 1 | Penicillin G | 2 | 23 | |||
Trimethoprim/Sulfamethoxazole | 207 | 1 | 1 | Trimethoprim/Sulfamethoxazole | 22 | ||||
Other CLSI groups | |||||||||
Chloramphenicol | 1 | Amikacin | 1 | ||||||
Ciprofloxacin | 120 | Chloramphenicol | 3 | ||||||
Daptomycin | 32 | 1 | Ciprofloxacin | 20 | |||||
Doxycycline | 1 | Doxycycline | 1 | ||||||
Gentamicin | 2 | 26 | 41 | Gentamicin | 1 | 1 | 14 | ||
Levofloxacin | 2 | Imipenem | 4 | ||||||
Linezolid | 203 | 1 | Kanamycin | 1 | |||||
Nitrofurantoin | 2 | Levofloxacin | 5 | 1 | |||||
Quinupristin/Dalfopristin | 4 | Linezolid | 6 | ||||||
Rifampicin | 54 | Minocycline | 1 | ||||||
Rifampin | 99 | 2 | Moxifloxacin | 1 | |||||
Teicoplanin | 30 | Netilmicin | 1 | ||||||
Telithromycin | 6 | ||||||||
Tetracycline | 205 | ||||||||
Tigecycline | 3 | ||||||||
Vancomycin | 224 | 6 | |||||||
Unacceptable | |||||||||
Ampicillin | 2 | 1 | Ampicillin | 4 | |||||
Ampicillin/Sulbactam | 1 | Cefamandole | 1 | 1 | |||||
Cefazolin | 1 | Cefazolin | 1 | ||||||
Imipenem | 1 | Cefmetazole | 1 | 1 | |||||
Norfloxacin | 1 | Cefoperazone | 1 | 1 | |||||
Cefotaxime | 1 | 1 | |||||||
Ceftriaxone | 6 | ||||||||
Cefuroxime axetil | 1 | ||||||||
Cefuroxime sodium | 1 | ||||||||
Meropenem | 1 | ||||||||
Piperacillin/Tazobactam | 1 |
Abbreviations: MIC, minimum inhibitory concentration; S, susceptible; I, intermediate; R, resistance; IND, indeterminate; CLSI, Clinical and Laboratory Standards Institute.